Your browser is no longer supported. Please, upgrade your browser.
TELA TELA Bio, Inc. daily Stock Chart
TELA Bio, Inc.
Index- P/E- EPS (ttm)-108.30 Insider Own17.50% Shs Outstand9.49M Perf Week21.92%
Market Cap76.01M Forward P/E- EPS next Y-2.23 Insider Trans0.00% Shs Float9.49M Perf Month-49.37%
Income- PEG- EPS next Q-0.60 Inst Own75.30% Short Float1.19% Perf Quarter-35.51%
Sales13.00M P/S5.85 EPS this Y-9.90% Inst Trans- Short Ratio2.17 Perf Half Y-
Book/sh-538.04 P/B- EPS next Y4.70% ROA- Target Price20.25 Perf Year-
Cash/sh1.13 P/C7.10 EPS next 5Y- ROE- 52W Range5.25 - 18.88 Perf YTD-38.15%
Dividend- P/FCF- EPS past 5Y- ROI18.40% 52W High-57.57% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin56.40% 52W Low52.57% ATR1.76
Employees86 Current Ratio2.80 Sales Q/Q81.80% Oper. Margin- RSI (14)36.49 Volatility18.67% 19.48%
OptionableNo Debt/Eq- EPS Q/Q-38.70% Profit Margin- Rel Volume2.79 Prev Close8.00
ShortableYes LT Debt/Eq- EarningsMar 27 BMO Payout- Avg Volume52.19K Price8.01
Recom1.50 SMA20-26.12% SMA50-42.26% SMA200-39.31% Volume145,541 Change0.13%
Dec-03-19Initiated Piper Jaffray Overweight
Dec-03-19Initiated JMP Securities Mkt Outperform
Dec-03-19Initiated Jefferies Buy
Dec-03-19Initiated Canaccord Genuity Buy
Mar-27-20 07:00AM  TELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
06:00AM  TELA Bio Inc to Host Earnings Call ACCESSWIRE
Mar-11-20 07:00AM  TELA Bio to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 27, 2020 GlobeNewswire -13.39%
Feb-04-20 04:15PM  TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia Repair GlobeNewswire
Jan-29-20 07:00AM  TELA Bio Announces Appointment of New Chief Commercial Officer GlobeNewswire
Jan-10-20 07:00AM  TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 GlobeNewswire
Dec-18-19 07:00AM  TELA Bio Announces Third Quarter 2019 Financial Results GlobeNewswire +11.46%
Dec-06-19 07:00AM  TELA Bio Awarded Contract with HealthTrust Purchasing Group GlobeNewswire
Nov-13-19 04:15PM  TELA Bio Appoints Federica OBrien to Board of Directors GlobeNewswire
04:05PM  TELA Bio Announces Closing of Initial Public Offering of Common Stock GlobeNewswire
Nov-08-19 06:17PM  Chinese Tech News Site 36Kr Flops in Tough Week for U.S. IPOs Bloomberg
Nov-07-19 08:00PM  TELA Bio Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company provides a portfolio of OviTex Reinforced Tissue Matrix or OviTex products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix or OviTex PRS products to address the unmet needs in plastic and reconstructive surgery. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.